ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

ALXO 11.26.2024

Full Press ReleaseSEC FilingsOur ALXO Tweets

About Gravity Analytica

Recent News

  • 01.23.2025 - ASPEN-06 ASCO GI Data Review
  • 01.23.2025 - ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
  • 01.23.2025 - Chris Takimoto, M.D., Ph.D., F.A.C.P.

Recent Filings

    PDF Version

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that Jason Lettmann, the Company’s Chief Executive Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held in New York City from December 3-5, 2024.

    Format: Fireside chat with analyst, Christopher Raymond and 1x1 meetingsDate: Tuesday, December 3, 2024Time: 9:30 AM ESTLocation: New York City, NYWebcast link: Availablehere

    The live webcast for the Piper Sandler fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website atwww.alxoncology.comand selectingEventsunder the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

    About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available atwww.alxoncology.comand on LinkedIn @ALX Oncology.

    Company Contact:Caitlyn Doherty, Manager, Corporate Communications, ALX Oncologycdoherty@alxoncology.com(650) 466-7125Investor Contact:Malini Chatterjee, Ph.D., Blueprint Life Science Groupmchatterjee@bplifescience.com(917) 330-4269Media Contact:Audra Friis, Sam Brown, Inc.audrafriis@sambrown.com(917) 519-9577

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com